vs

Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.

PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $113.9M, roughly 1.4× Riley Exploration Permian, Inc.). Riley Exploration Permian, Inc. runs the higher net margin — -61.8% vs -82.0%, a 20.1% gap on every dollar of revenue. On growth, Riley Exploration Permian, Inc. posted the faster year-over-year revenue change (11.2% vs -22.7%). Riley Exploration Permian, Inc. produced more free cash flow last quarter ($24.6M vs $-36.6M). Over the past eight quarters, Riley Exploration Permian, Inc.'s revenue compounded faster (3.9% CAGR vs -11.5%).

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

PTCT vs REPX — Head-to-Head

Bigger by revenue
PTCT
PTCT
1.4× larger
PTCT
$164.7M
$113.9M
REPX
Growing faster (revenue YoY)
REPX
REPX
+33.9% gap
REPX
11.2%
-22.7%
PTCT
Higher net margin
REPX
REPX
20.1% more per $
REPX
-61.8%
-82.0%
PTCT
More free cash flow
REPX
REPX
$61.2M more FCF
REPX
$24.6M
$-36.6M
PTCT
Faster 2-yr revenue CAGR
REPX
REPX
Annualised
REPX
3.9%
-11.5%
PTCT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
PTCT
PTCT
REPX
REPX
Revenue
$164.7M
$113.9M
Net Profit
$-135.0M
$-70.4M
Gross Margin
Operating Margin
-43.3%
38.3%
Net Margin
-82.0%
-61.8%
Revenue YoY
-22.7%
11.2%
Net Profit YoY
-104.8%
EPS (diluted)
$-1.63
$-3.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTCT
PTCT
REPX
REPX
Q1 26
$113.9M
Q4 25
$164.7M
$97.3M
Q3 25
$211.0M
$106.9M
Q2 25
$178.9M
$85.4M
Q1 25
$1.2B
$102.5M
Q4 24
$213.2M
$102.7M
Q3 24
$196.8M
$102.3M
Q2 24
$186.7M
$105.4M
Net Profit
PTCT
PTCT
REPX
REPX
Q1 26
$-70.4M
Q4 25
$-135.0M
Q3 25
$15.9M
$16.3M
Q2 25
$-64.8M
$30.5M
Q1 25
$866.6M
$28.6M
Q4 24
$-65.9M
Q3 24
$-106.7M
$25.7M
Q2 24
$-99.2M
$33.5M
Operating Margin
PTCT
PTCT
REPX
REPX
Q1 26
38.3%
Q4 25
-43.3%
26.9%
Q3 25
1.4%
27.0%
Q2 25
-19.5%
33.7%
Q1 25
82.5%
48.3%
Q4 24
-76.2%
31.2%
Q3 24
-27.7%
17.1%
Q2 24
-21.5%
50.9%
Net Margin
PTCT
PTCT
REPX
REPX
Q1 26
-61.8%
Q4 25
-82.0%
Q3 25
7.5%
15.3%
Q2 25
-36.3%
35.7%
Q1 25
73.7%
27.9%
Q4 24
-30.9%
Q3 24
-54.2%
25.1%
Q2 24
-53.1%
31.8%
EPS (diluted)
PTCT
PTCT
REPX
REPX
Q1 26
$-3.38
Q4 25
$-1.63
$4.02
Q3 25
$0.20
$0.77
Q2 25
$-0.83
$1.44
Q1 25
$10.04
$1.36
Q4 24
$-0.85
$0.52
Q3 24
$-1.39
$1.21
Q2 24
$-1.29
$1.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTCT
PTCT
REPX
REPX
Cash + ST InvestmentsLiquidity on hand
$1.9B
Total DebtLower is stronger
$240.7M
Stockholders' EquityBook value
$-205.3M
$553.4M
Total Assets
$2.9B
$1.2B
Debt / EquityLower = less leverage
0.43×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTCT
PTCT
REPX
REPX
Q1 26
Q4 25
$1.9B
Q3 25
$1.7B
Q2 25
$2.0B
Q1 25
$2.0B
Q4 24
$1.1B
Q3 24
$1.0B
Q2 24
$1.1B
Total Debt
PTCT
PTCT
REPX
REPX
Q1 26
$240.7M
Q4 25
$247.9M
Q3 25
$367.0M
Q2 25
$275.2M
Q1 25
$249.3M
Q4 24
$269.5M
Q3 24
$288.6M
Q2 24
$322.7M
Stockholders' Equity
PTCT
PTCT
REPX
REPX
Q1 26
$553.4M
Q4 25
$-205.3M
$634.2M
Q3 25
$-155.8M
$566.5M
Q2 25
$-206.5M
$556.9M
Q1 25
$-185.8M
$532.4M
Q4 24
$-1.1B
$510.6M
Q3 24
$-1.1B
$507.4M
Q2 24
$-980.2M
$489.0M
Total Assets
PTCT
PTCT
REPX
REPX
Q1 26
$1.2B
Q4 25
$2.9B
$1.2B
Q3 25
$2.6B
$1.2B
Q2 25
$2.6B
$1.0B
Q1 25
$2.7B
$994.9M
Q4 24
$1.7B
$993.5M
Q3 24
$1.8B
$997.9M
Q2 24
$1.9B
$1.0B
Debt / Equity
PTCT
PTCT
REPX
REPX
Q1 26
0.43×
Q4 25
0.39×
Q3 25
0.65×
Q2 25
0.49×
Q1 25
0.47×
Q4 24
0.53×
Q3 24
0.57×
Q2 24
0.66×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTCT
PTCT
REPX
REPX
Operating Cash FlowLast quarter
$-34.3M
$47.2M
Free Cash FlowOCF − Capex
$-36.6M
$24.6M
FCF MarginFCF / Revenue
-22.3%
21.6%
Capex IntensityCapex / Revenue
1.4%
41.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$702.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTCT
PTCT
REPX
REPX
Q1 26
$47.2M
Q4 25
$-34.3M
$64.9M
Q3 25
$-66.3M
$63.6M
Q2 25
$-58.3M
$33.6M
Q1 25
$870.1M
$50.4M
Q4 24
$-30.0M
$66.4M
Q3 24
$-77.0M
$72.1M
Q2 24
$-71.5M
$51.6M
Free Cash Flow
PTCT
PTCT
REPX
REPX
Q1 26
$24.6M
Q4 25
$-36.6M
Q3 25
$-69.7M
Q2 25
$-59.6M
Q1 25
$868.4M
Q4 24
$-33.8M
Q3 24
$-77.5M
Q2 24
$-78.8M
FCF Margin
PTCT
PTCT
REPX
REPX
Q1 26
21.6%
Q4 25
-22.3%
Q3 25
-33.1%
Q2 25
-33.3%
Q1 25
73.8%
Q4 24
-15.8%
Q3 24
-39.4%
Q2 24
-42.2%
Capex Intensity
PTCT
PTCT
REPX
REPX
Q1 26
41.3%
Q4 25
1.4%
Q3 25
1.6%
Q2 25
0.7%
Q1 25
0.1%
Q4 24
1.8%
Q3 24
0.3%
Q2 24
4.0%
Cash Conversion
PTCT
PTCT
REPX
REPX
Q1 26
Q4 25
Q3 25
-4.17×
3.90×
Q2 25
1.10×
Q1 25
1.00×
1.76×
Q4 24
Q3 24
2.81×
Q2 24
1.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons